These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30391313)

  • 1. Mathematical modelling of liposomal drug release to tumour.
    Chakravarty K; Dalal DC
    Math Biosci; 2018 Dec; 306():82-96. PubMed ID: 30391313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Nonlinear Mathematical Model of Drug Delivery from Polymeric Matrix.
    Chakravarty K; Dalal DC
    Bull Math Biol; 2019 Jan; 81(1):105-130. PubMed ID: 30298197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic study of temperature sensitive liposomal delivery of doxorubicin using a mathematical model.
    Liu C; Xu XY
    Comput Biol Med; 2015 May; 60():107-16. PubMed ID: 25817532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New generation of liposomal drugs for cancer.
    Minko T; Pakunlu RI; Wang Y; Khandare JJ; Saad M
    Anticancer Agents Med Chem; 2006 Nov; 6(6):537-52. PubMed ID: 17100558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Unified Mathematical Model for Nano-Liposomal Drug Delivery to Solid Tumors.
    Asemani D; Haemmerich D
    IEEE Trans Nanobioscience; 2018 Mar; 17(1):3-11. PubMed ID: 29570070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
    Gabizon A; Shmeeda H; Barenholz Y
    Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review on triggered liposomal drug delivery with a focus on ultrasound.
    Moussa HG; Martins AM; Husseini GA
    Curr Cancer Drug Targets; 2015; 15(4):282-313. PubMed ID: 25760762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery.
    Lee RJ; Wang S; Turk MJ; Low PS
    Biosci Rep; 1998 Apr; 18(2):69-78. PubMed ID: 9743475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
    Gabizon A; Martin F
    Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
    Andresen TL; Jensen SS; Jørgensen K
    Prog Lipid Res; 2005 Jan; 44(1):68-97. PubMed ID: 15748655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomes. Opportunities in drug delivery.
    Allen TM
    Drugs; 1997; 54 Suppl 4():8-14. PubMed ID: 9361956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2.
    Andresen TL; Jensen SS; Kaasgaard T; Jørgensen K
    Curr Drug Deliv; 2005 Oct; 2(4):353-62. PubMed ID: 16305438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of liposome encapsulated temozolomide to brain tumour: Understanding the drug transport for optimisation.
    Zhan W
    Int J Pharm; 2019 Feb; 557():280-292. PubMed ID: 30599226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
    Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
    Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.
    Gilabert-Oriol R; Ryan GM; Leung AWY; Firmino NS; Bennewith KL; Bally MB
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
    Krishna R; Mayer LD
    Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of liposomal anticancer drugs.
    Hyodo K; Yamamoto E; Suzuki T; Kikuchi H; Asano M; Ishihara H
    Biol Pharm Bull; 2013; 36(5):703-7. PubMed ID: 23649329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of ligand-targeted liposomes for cancer therapy.
    Noble CO; Kirpotin DB; Hayes ME; Mamot C; Hong K; Park JW; Benz CC; Marks JD; Drummond DC
    Expert Opin Ther Targets; 2004 Aug; 8(4):335-53. PubMed ID: 15268628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-selective drug delivery via folate receptor-targeted liposomes.
    Pan X; Lee RJ
    Expert Opin Drug Deliv; 2004 Nov; 1(1):7-17. PubMed ID: 16296717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.